- Home
- MX vs MOLN Comparison
MX vs MOLN Comparison
Compare MX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MX | MOLN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | South Korea | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 143.3M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MX | MOLN |
|---|---|---|
| Price | $3.38 | $4.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.75 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 1.4M | 9.8K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $178,860,000.00 | N/A |
| Revenue This Year | $8.55 | N/A |
| Revenue Next Year | $6.37 | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $3.41 |
| 52 Week High | $9.86 | $5.36 |
Technical Indicators
Market Signals| Indicator | MX | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 52.60 |
| Support Level | $2.45 | $3.94 |
| Resistance Level | $4.76 | $4.14 |
| Average True Range (ATR) | 0.28 | 0.11 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 6.41 | 71.29 |
Price Performance
Historical ComparisonAbout MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.